These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
317 related articles for article (PubMed ID: 10260202)
41. Activities, functions, and structure of pharmacy and therapeutics committees in large teaching hospitals. Mannebach MA; Ascione FJ; Gaither CA; Bagozzi RP; Cohen IA; Ryan ML Am J Health Syst Pharm; 1999 Apr; 56(7):622-8. PubMed ID: 10423208 [TBL] [Abstract][Full Text] [Related]
42. Target drug monitoring: a cost-effective service provided by staff pharmacists. Chrymko MM; Meyer JD; Kelly WN Hosp Pharm; 1994 Apr; 29(4):347, 350-2. PubMed ID: 10133463 [TBL] [Abstract][Full Text] [Related]
43. Drug usage review and inventory analysis in promoting rational parenteral cephalosporin therapy. Simon WA; Thompson L; Campbell S; Lantos RL Am J Hosp Pharm; 1975 Nov; 32(11):1116-21. PubMed ID: 1190230 [TBL] [Abstract][Full Text] [Related]
44. Editors' roundtable: Current formulas for P & T Committee success (Part 1). Lipman AG; Neu HC; Singh BN; Weintraub M Hosp Formul; 1987 Mar; 22(3):288-98. PubMed ID: 10312015 [TBL] [Abstract][Full Text] [Related]
46. The evolutionary role of the pharmacy and therapeutics committee in technology assessment. Mehr SR Manag Care Interface; 2006 Jan; 19(1):42-5. PubMed ID: 16453995 [TBL] [Abstract][Full Text] [Related]
47. Managing conflicts of interest in pharmacy and therapeutics committees: A proposal for multicentre formulary development. Friesen P; Caplan AL; Miller JE J Clin Pharm Ther; 2020 Apr; 45(2):249-255. PubMed ID: 31657022 [TBL] [Abstract][Full Text] [Related]
48. P & T Committee interview: communication and education contribute to an effective formulary system. Hinthorn D; Godwin H Hosp Formul; 1989 May; 24(5):281-4, 286-7. PubMed ID: 10292977 [TBL] [Abstract][Full Text] [Related]
50. Formulary system controversies in the new environment of DRGs. Lipman AG Hosp Formul; 1985 Feb; 20(2):218, 221-4, 229 passim. PubMed ID: 10311021 [TBL] [Abstract][Full Text] [Related]
51. Preparing the P & T committee agenda for new drug requests. Standish RC; Evans PJ; Bell JE Hosp Formul; 1984 Sep; 19(9):792, 795-800. PubMed ID: 10267929 [TBL] [Abstract][Full Text] [Related]
52. P & T Committee interview: strategies to ensure an effective formulary system. Riff L; Hutchinson R Hosp Formul; 1988 Nov; 23(11):901-4, 907-8. PubMed ID: 10290754 [TBL] [Abstract][Full Text] [Related]
53. Legal aspects of clinical pharmacy practice. Clark JE; Nwangwu PU Contemp Pharm Pract; 1982; 5(3):198-203. PubMed ID: 10256922 [TBL] [Abstract][Full Text] [Related]
54. JCAHO--clinical indicators--a glimpse into the future. Hoffmann RP Hosp Pharm; 1989 Jan; 24(1):63-4. PubMed ID: 10291603 [No Abstract] [Full Text] [Related]
55. How a CQI program improved aminoglycoside use in a community hospital. Wade WE; McCall CY Hosp Formul; 1995 Feb; 30(2):114-6. PubMed ID: 10140350 [TBL] [Abstract][Full Text] [Related]
56. Cost containment through P & T committee drug utilization review. Bender FH; DeMatteo CS Hosp Formul; 1984 Aug; 19(8):699-700, 705-7. PubMed ID: 10267391 [TBL] [Abstract][Full Text] [Related]
57. [Drug committees in Denmark. Status and future challenges]. Rabøl R; Kampmann JP; Christensen HR Ugeskr Laeger; 2004 Aug; 166(35):2988-91. PubMed ID: 15387009 [No Abstract] [Full Text] [Related]
58. Implementing and maintaining a viable formulary. Kelly WN; Bender FH Hosp Formul; 1983 Oct; 18(10):976-8, 981-2, 987. PubMed ID: 10262828 [No Abstract] [Full Text] [Related]
59. Legal and medical issues in therapeutic interchange: implications for pharmacists, physicians, and P & T committees. Plumeri PA; Crane VS Hosp Formul; 1992 Oct; 27(10):1040-2, 1047-8. PubMed ID: 10121419 [TBL] [Abstract][Full Text] [Related]
60. Appraising purposes and functions of the P. and T. committee. Katcher AL Hosp Top; 1969 Feb; 47(2):61-6. PubMed ID: 4975066 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]